Question · asked by 1 review
Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo: Number of days unable to take medicine orally
- Population
- Adults with cancer receiving treatment
- Intervention
- Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous
- Comparison
- placebo
- Outcome
- Number of days unable to take medicine orally
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Placebo Number of days unable to take medicine orally · Adults with cancer receiving treatment The review found no eligible studies for this question. Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and… (2017) · Cochrane All outcomes | No studies reported this outcome (planned secondary outcome not measured by any study in the review) | 0 studies | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes | 2017-05 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.